Xanax

IMPORTANT SAFETY INFORMATION AND INDICATION
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
  • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
  • Limit dosages and durations to the minimum required.
  • Follow patients for signs and symptoms of respiratory depression and sedation.
Contraindications:
XANAX tablets are contraindicated in patients with known sensitivity to alprazolam or other benzodiazepines.
XANAX is contraindicated with ketoconazole and itraconazole, since these medications significantly impair the oxidative metabolism mediated by cytochrome P450 3A (CYP3A).
Warnings and Precautions:
Certain adverse clinical events, some life-threatening, are a direct consequence of physical dependence of XANAX. These include a spectrum of withdrawal symptoms; the most important is seizure. Whether XANAX is taken for a short or long period of time patients should be tapered gradually to zero dose instead of abrupt discontinuation. Withdrawal reactions may occur when dosage reduction occurs for any reason.
Withdrawal seizures have been reported in association with the discontinuation of XANAX. Abrupt discontinuation of treatment should be avoided.
Patients should not operate machinery or drive motor vehicles while taking XANAX. Caution patients on the use of alcohol and other CNS depressant drugs during treatment with XANAX.
Benzodiazepines can potentially cause fetal harm when administered to pregnant women. XANAX is assumed to be capable of causing an increased risk of congenital abnormalities when administered to pregnant women during the first trimester and administration should be avoided. XANAX should be prescribed with caution to women of childbearing potential.
Benzodiazepines are known to be excreted in human milk, and it should be assumed that alprazolam is, as well. As a general rule, nursing should not be undertaken by mothers who must use XANAX.
XANAX should be avoided in patients receiving very potent inhibitors of CYP3A (azole antifungal agents- ketoconazole and itraconazole, as well as nefazodone, fluvoxamine, and erythromycin).
XANAX dose reductions are recommended during coadministration with nefazodone, fluvoxamine, cimetidine, and HIV protease inhibitors.
As with other psychotropic medications, the usual precautions with respect to administration of the drug and size of the prescription are indicated for severely depressed patients or those in whom there is reason to expect concealed suicidal ideation or plans. Panic disorder has been associated with primary and secondary major depressive disorders and increased reports of suicide among untreated patients.
Hypomania and mania have been reported in association with the use of XANAX in patients with depression.
XANAX should be limited to the smallest effective dose to preclude the development of ataxia or over-sedation, which may be a problem in elderly or debilitated patients. The usual precautions in treating patients with impaired renal, hepatic or pulmonary function should be observed.
The most commonly observed adverse reactions in patients taking XANAX vs placebo for anxiety disorders in clinical studies (incidence ≥5% and twice the rate of placebo) were drowsiness, light-headedness and dry mouth). The most commonly observed adverse reactions in patients taking XANAX vs placebo for panic disorder in clinical studies (incidence ≥5% and twice the rate of placebo) were impaired coordination (40.1% vs 17.9%), dysarthria (23.3% vs 6.3%) and sexual dysfunction (7.4% vs 3.7).

INDICATION

XANAX (alprazolam) tablets are indicated for the management of generalized anxiety disorder, or the short-term relief of symptoms of anxiety in adults, including anxiety associated with depression, and Panic Disorder in adults, with or without agoraphobia.

TERMS AND CONDITIONS

By using the XANAX Savings Card (the “Card”), you attest that you meet the eligibility criteria and will comply with the Terms and Conditions described below:
You will pay $4 for a 30-day supply (30 tablets) if: Your out-of-pocket expense for a 30-day supply of brand-name XANAX is $129 or less.
Patients can receive a maximum savings of $1500 per year.
This offer is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico [formerly known as “La Reforma de Salud”]).
This Card cannot be combined with any other rebate/coupon, free trial, discount, prescription savings card, or similar offer for the specified prescription.
The Card will be accepted only at participating pharmacies.
This Card is not health insurance.
Offer valid only in the U.S. and Puerto Rico, but not for Massachusetts residents or where otherwise prohibited by law.
This Card is limited to 1 use per person per month during this offering period and is not transferable. It is illegal to sell, purchase, trade, or counterfeit, or offer to sell, purchase, trade, or counterfeit this Card.
Pfizer reserves the right to rescind, revoke, or amend the Card Program without notice at any time.
You must be 18 or older to participate in this Program.
Card Program membership expires December 31, 2018.
No membership fees.
For questions about this Card, please call 1-855-854-4535, visit Xanax.com, or write to the address below.
    For reimbursement when using a mail-order pharmacy, please submit the following via mail:
  • A copy of your XANAX Savings Card
  • Your original proof of purchase (original pharmacy receipt, cash register receipt NOT valid), with the pharmacy name, product name, prescription numbers, NDC number, date filled, quantity, and price circled
  • A photocopy of the front and back of your insurance card
  • Your date of birth, name, and mailing address
Mail all of the information to:
XANAX Claims Processing Department
PO Box 1785
New York, NY 10156
Please allow 6-8 weeks to receive your reimbursement. Reimbursement requests must be postmarked within 4 weeks of fill date.

Are your patients in need of prescription assistance?

Pfizer RxPathways® connects eligible patients to assistance programs that offer insurance support, co-pay assistance, and medicines for free or at a savings.

Learn more by visiting
www.PfizerRxPathways.com or
calling 1-844-989-PATH (7284)